Added to YB: 2025-05-28
Pitch date: 2025-05-27
FULC [neutral]
Fulcrum Therapeutics, Inc.
+107.01%
current return
Author Info
Stock Pursuit researches domestic deep value equities below net cash, net current asset value or net tangible assets. Sign up for the newsletter.
Company Info
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States.
Market Cap
$468.1M
Pitch Price
$6.28
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.54
P/E
-7.57
EV/Sales
N/A
Sector
Pharmaceuticals
Category
N/A
Fulcrum Therapeutics, Inc. - $FULC
FULC (sell): Recently up 110% to $7, time to sell. Lead drug Pociredir (FTX-6058) for Sickle Cell Disease shows promise but faces hurdles. Analysts increased peak sales est. to $600M, 50% success probability. Cash into 2027. Pfizer's Oxbryta withdrawal creates opportunity. Worth keeping small position (10%) as insurance.
Read full article (2 min)